Date: 2015-08-10
Type of information: Initiation of the trial
phase:
Announcement: initiation of the trial
Company: Argos Therapeutics (USA - NC)
Product: AGS-003
Action
mechanism: cell immunotherapy. AGS-003 is an autologous immunotherapy that is prepared using a patient's own dendritic cells and amplified tumor RNA.
Disease: renal cell carcinoma
Therapeutic area: Cancer - Oncology
Country: USA
Trial details:
Latest
news: * On August 10, 2015, Argos Therapeutics, an immunooncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, announced the initiation of a single-center pilot clinical trial of AGS-003 as a neoadjuvant immunotherapy in patients with localized renal cell carcinoma. The study is being conducted at Roswell Park Cancer Institute (RPCI) in Buffalo, New York, and is designed to enroll a maximum of ten patients who will be treated with AGS-003 before nephrectomy in order to assess immune system response and tumor effects. The pilot study is in patients with localized renal cell carcinoma, who must be eligible to undergo a partial or radical nephrectomy. Patients will receive five weekly doses of AGS-003 prior to surgery and will remain in the study for approximately six months.
